Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Maria M RubinsteinDavid M HymanImogen CairdHelen WonKrysten SoldanKenneth SeierAlexia IasonosWilliam P TewRoisin E O'CearbhaillRachel N GrishamMartee L HensleyTiffany Troso-SandovalPaul SabbatiniJoyce GuillenS Duygu SelcukluCatherine ZimelJean TorrisiCarol AghajanianVicky MakkerPublished in: Cancer (2019)
In patients with heavily pretreated advanced endometrial cancer prospectively selected for tumors with activating PI3K pathway mutations, LY3023414 demonstrated modest single-agent activity and a manageable safety profile.